Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie: 3 Key Takeaways for Long-Term Investors
31.10.2026 14:51
Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.
Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?
31.10.2026 10:14
AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share starting with the February 16, 2027 payment. The stronger outlook rests on AbbVie’s immunology and neuroscience engines, with products like SKYRIZI, RINVOQ and newer launches offsetting pressure on older therapies such as Humira and Imbruvica, while the oncology and migraine pipelines...
Stock Market Today: Nasdaq Futures Plunge 2% as Big Tech Sells Off
30.10.2026 13:32
Big Tech is dragging the Nasdaq toward its worst open in weeks while Dow components post earnings beats and barely budge. Whether the damage stays contained or spreads to the broader market depends on what happens the moment the opening bell rings.
AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates
30.10.2026 13:11
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts’ consensus estimates.
Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings
30.10.2026 13:00
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again
30.10.2026 12:47
AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi.
AbbVie beats estimates but stock dips
30.10.2026 12:25
Investing.com -- AbbVie Inc. (NYSE:ABBV) reported third-quarter results that exceeded analyst expectations, though shares are down 3% premarket as the company's raised full-year guidance came in largely in line with Wall Street estimates.
AbbVie (NYSE:ABBV) Q3 2026 Results In Line With Estimates as Guidance and Dividend Rise
30.10.2026 12:20
AbbVie’s Q3 2026 results were in line with estimates; raised guidance and dividend signal confidence despite a slightly lower pre-market reaction.
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates
30.10.2026 11:55
AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie: Q3 Earnings Snapshot
30.10.2026 11:54
(ABBV) on Friday reported third-quarter earnings of $4.The North Chicago, Illinois-based company said it had net income of $2.
AbbVie Reports Third-Quarter 2026 Financial Results
30.10.2026 11:46
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026.
AbbVie Q3 2026 Earnings Call Transcript
30.10.2026 10:31
AbbVie (NYSE:ABBV) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
AbbVie Exec Says Co. Expects More Bolt-On Deals Rather Than Large Transformational Deal Like Allergan; Co. Has Continued Interest In Building Out Obesity Assets And Is Open To Anything With A Differentiated Profile That Could Match Its Abbv-295
30.10.2026 10:07
https://edge.media-server.com/mmc/p/qvczs2fg
AbbVie Exec Says Co. Expects Q4 Revenue Of About $18.4B, Which Includes Modestly Unfavorable Impact From Foreign Exchange; Says It Is Too Early To Call A Financial Impact From The 340B Rebate Pilot
30.10.2026 10:01
https://edge.media-server.com/mmc/p/qvczs2fg
Conference call: AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est
30.10.2026 09:44
AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
30.10.2026 09:43
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.
AbbVie Raises FY2026 Adj EPS Guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 Est
30.10.2026 07:51
AbbVie (NYSE:ABBV) raises FY2026 Adj EPS guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 analyst estimate..
AbbVie Q3 Adj. EPS $3.82 Beats $3.75 Estimate, Sales $17.404B Beat $17.314B Estimate
30.10.2026 07:47
AbbVie (NYSE:ABBV) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.75 by 1.87 percent. This is a 105.38 percent increase over earnings of $1.86 per share from the same
AbbVie (ABBV) Stock Still Looks Cheap On Its 197% Five Year Run
30.10.2026 00:14
AbbVie has ridden a strong multi year run in the market, and the question now is whether the current share price lines up with the cash flows its business can realistically generate. With fresh drug trial results and regulatory milestones in the spotlight, investors are increasingly asking how much of that story is already reflected in the valuation. Over the past 5 years AbbVie has delivered a 196.7% share price return, which puts real pressure on the numbers to show that today’s valuation...
AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple Myeloma
28.10.2026 16:16
AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the FDA for its multiple myeloma candidate etentamig. The filing is backed by a pivotal Phase 3 trial in relapsed or refractory multiple myeloma that met its primary endpoint. Etentamig is a second generation BCMA x CD3 bispecific antibody that is administered on a monthly dosing schedule. There is more to AbbVie than the new etentamig BLA, starting with other oncology and immunology efforts. We have also flagged 4 warning...